Wordt geladen...
Similar effectiveness of dapagliflozin and GLP‐1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study
AIMS: According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous...
Bewaard in:
| Gepubliceerd in: | Diabetes Obes Metab |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Blackwell Publishing Ltd
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767088/ https://ncbi.nlm.nih.gov/pubmed/30985052 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13747 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|